Prime Medicine
PRME
187 hedge funds and large institutions have $393M invested in Prime Medicine in 2026 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 67 reducing their positions, and 23 closing their positions.
145% more capital inflows, than outflows
Capital inflows: $45.8M | Capital outflows: $18.7M
4.45% more ownership
Funds ownership: 54.59% → 59.04% (+4.5%)
0% less call options, than puts
Call options by funds: $2.84M | Put options by funds: $2.85M
4% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 23
4% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 67
3% less funds holding
Funds holding: 192 → 187 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.17M |
| 2 |
ARK Investment Management
St. Petersburg,
Florida
|
+$6.98M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.71M |
| 4 |
Jump Financial
Chicago,
Illinois
|
+$4.12M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$2.47M |
| 2 |
Renaissance Technologies
New York
|
-$2.07M |
| 3 |
Nikko Asset Management Americas
New York
|
-$1.77M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$1.75M |
| 5 |
HRT Financial
New York
|
-$1.5M |
PRME Hedge Fund Activity: Q2 2026 in Review
187 of the 8,353 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q2 2026, worth a combined $393M — up 15% from $343M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PRME and 22 opened new positions — a net loss of 1 holder — while 67 trimmed existing stakes and 64 added.
The largest buyer was Goldman Sachs, adding an estimated $8.17M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.47M.
- 187 institutional investors held Prime Medicine (PRME) as of Q2 2026, down from 192 in Q1 2026.
- Funds reported $393M of Prime Medicine stock for Q2 2026, up 15% quarter-over-quarter.
- 22 funds opened new Prime Medicine positions in Q2 2026 and 23 closed out, a net change of -1 holder.
- The largest Prime Medicine buyer in Q2 2026 was Goldman Sachs, an estimated $8.17M added.
- The largest Prime Medicine seller in Q2 2026 was D.E. Shaw & Co, an estimated $2.47M sold.
Based on aggregated 13F filings for Q2 2026.